AADI BIOSCIENCES
(NASDAQ: AADI)

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

3.390

+1.070 (+46.12%)
Range 2.070 - 3.600   (73.91%)
Open 2.520
Previous Close 2.320
Bid Price 8.140
Bid Volume 8
Ask Price 8.200
Ask Volume 30
Volume 8,803,871
Value -
Remark
Delayed prices. Updated at 21 Dec 2024 05:00.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis